SRR661445
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.289
- SPERMATOGENESIS+0.220
- ANDROGEN_RESPONSE+0.144
- KRAS_SIGNALING_DN+0.120
- PEROXISOME+0.114
- OXIDATIVE_PHOSPHORYLATION+0.112
- HEME_METABOLISM+0.109
- ADIPOGENESIS+0.087
- HEDGEHOG_SIGNALING+0.078
- BILE_ACID_METABOLISM+0.070
Top 10 suppressed
- TNFA_SIGNALING_VIA_NFKB-0.385
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.341
- TGF_BETA_SIGNALING-0.322
- ANGIOGENESIS-0.311
- WNT_BETA_CATENIN_SIGNALING-0.310
- MITOTIC_SPINDLE-0.307
- MYC_TARGETS_V2-0.298
- G2M_CHECKPOINT-0.297
- ALLOGRAFT_REJECTION-0.290
- INTERFERON_ALPHA_RESPONSE-0.275
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR655134 | GTEX | — | 0.894 |
| 2 | SRR655218 | GTEX | — | 0.885 |
| 3 | SRR1420984 | GTEX | — | 0.875 |
| 4 | SRR657754 | GTEX | — | 0.873 |
| 5 | SRR1336660 | GTEX | — | 0.862 |
| 6 | BS_ZRM0W01M | low-grade glioma | — | 0.858 |
| 7 | SRR1096966 | GTEX | — | 0.851 |
| 8 | SRR657683 | GTEX | — | 0.850 |
| 9 | BS_N6NE6B3W | pilocytic astrocytoma | — | 0.846 |
| 10 | SRR8518272 | — | E | 0.844 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 15 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.289 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.220 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.144 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.120 | Remibrutinib | — uncovered |
| PEROXISOME | 0.114 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.112 | Remibrutinib | — uncovered |
| HEME_METABOLISM | 0.109 | Temsirolimus | — uncovered |
| ADIPOGENESIS | 0.087 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.078 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.070 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.067 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.049 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.044 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.022 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.012 | Inavolisib | — uncovered |